Search results
Results from the WOW.Com Content Network
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
In comparable short-term (4-6 week) acute schizophrenia clinical trials, the percentage of patients taking a third-generation antipsychotic that had clinically relevant weight gain (>= 7% gain) was 9.2% for aripiprazole vs 4.3% for placebo, 10.4% for brexpiprazole vs 4.1% for placebo, and 9.2% for cariprazine vs 4.7% for placebo.
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
[1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2] [3] The FDA considers it to be a first-in-class medication. [4]
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
[5] [6] For comparison, dopamine D 2 receptor occupancy of 65 to 80% is associated with antipsychotic-like effects and hence with substantial postsynaptic dopamine D 2 receptor antagonism in animals. [8] [9] ENX-104 has been found to increase dopamine and serotonin levels in the nucleus accumbens and prefrontal cortex. [6]
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.
Ulotaront (INN Tooltip International Nonproprietary Name; [1] developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis.